Group 1 - The core viewpoint of the article highlights that Fosun Pharma's stock price increased nearly 5% in early trading, reflecting positive market sentiment following the release of its mid-year results for 2025 [1] - Fosun Pharma reported a revenue of approximately 19.514 billion yuan, a year-on-year decrease of 4.63%, while the net profit attributable to shareholders was about 1.702 billion yuan, showing a significant year-on-year increase of 38.96% [1] - The basic earnings per share were reported at 0.64 yuan, indicating a solid performance in terms of profitability despite the decline in overall revenue [1] Group 2 - The company experienced robust growth in its innovative drug segment, with revenues exceeding 4.3 billion yuan, representing a year-on-year increase of 14.26% [1] - The increase in profit was primarily attributed to the gains from the sale of remaining equity in United Family Healthcare and other non-core assets [1] - Fosun Pharma announced a licensing agreement with Sitala for the development, production, and commercialization of FXS6837 and related products outside of China, which is expected to accelerate clinical development and expand the company's international product portfolio [1]